Business Standard

Pharma, healthcare Q3FY23 preview: Cost pressures abating to aid margins

Hospitals are expected to report a soft Q3 result due to a mix of seasonality and easing pent-up demand, however, average revenue per occupied bed is likely to remain steady

Premium

Sohini Das Mumbai
Analysts expect pharma and healthcare companies to report a modest growth in Q3FY23, supported by healthy domestic market performance, tapering down of raw material and freight costs, and easing pricing pressures in the US coupled with a strong flu season.

Hospitals are expected to report a soft Q3 result due to a mix of seasonality and easing pent-up demand, however, average revenue per occupied bed (ARPOB) is likely to remain steady. In diagnostics, analysts model in high-single digit year-on-year (YoY) volume growth in core business, but margins are under pressure from competition.

Analysts at Nuvama Research said that

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jan 18 2023 | 6:03 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com